Docality.com Logo
 
Dr. Manzoor  Tariq  Md image

Dr. Manzoor Tariq Md

1071 Airport Road
Festus MO 63028
636 317-7111
Medical School: Other - 1980
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: Yes
License #: 100167
NPI: 1134237332
Taxonomy Codes:
207RC0000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Manzoor Tariq is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:37229 Description:Tib/per revasc w/ather Average Price:$28,000.00 Average Price Allowed
By Medicare:
$10,412.67
HCPCS Code:93460 Description:R&l hrt art/ventricle angio Average Price:$14,200.00 Average Price Allowed
By Medicare:
$972.34
HCPCS Code:93459 Description:L hrt art/grft angio Average Price:$13,250.00 Average Price Allowed
By Medicare:
$787.29
HCPCS Code:93458 Description:L hrt artery/ventricle angio Average Price:$12,700.00 Average Price Allowed
By Medicare:
$857.26
HCPCS Code:92980 Description:Insert intracoronary stent Average Price:$8,100.00 Average Price Allowed
By Medicare:
$725.14
HCPCS Code:36247 Description:Ins cath abd/l-ext art 3rd Average Price:$8,500.00 Average Price Allowed
By Medicare:
$1,506.39
HCPCS Code:36252 Description:Ins cath ren art 1st bilat Average Price:$7,845.00 Average Price Allowed
By Medicare:
$1,305.77
HCPCS Code:36245 Description:Ins cath abd/l-ext art 1st Average Price:$6,800.00 Average Price Allowed
By Medicare:
$1,577.97
HCPCS Code:37205 Description:Transcath iv stent percut Average Price:$9,000.00 Average Price Allowed
By Medicare:
$4,204.62
HCPCS Code:36246 Description:Ins cath abd/l-ext art 2nd Average Price:$5,000.00 Average Price Allowed
By Medicare:
$516.54
HCPCS Code:37225 Description:Fem/popl revas w/ather Average Price:$15,000.00 Average Price Allowed
By Medicare:
$10,651.05
HCPCS Code:75685 Description:Artery x-rays spine Average Price:$4,300.00 Average Price Allowed
By Medicare:
$219.46
HCPCS Code:93458 Description:L hrt artery/ventricle angio Average Price:$4,000.00 Average Price Allowed
By Medicare:
$289.72
HCPCS Code:36215 Description:Place catheter in artery Average Price:$4,000.00 Average Price Allowed
By Medicare:
$570.60
HCPCS Code:75625 Description:Contrast x-ray exam of aorta Average Price:$3,521.43 Average Price Allowed
By Medicare:
$183.22
HCPCS Code:75650 Description:Artery x-rays head & neck Average Price:$2,900.00 Average Price Allowed
By Medicare:
$202.03
HCPCS Code:75716 Description:Artery x-rays arms/legs Average Price:$2,781.44 Average Price Allowed
By Medicare:
$237.15
HCPCS Code:75710 Description:Artery x-rays arm/leg Average Price:$2,600.00 Average Price Allowed
By Medicare:
$202.74
HCPCS Code:75960 Description:Transcath iv stent rs&i Average Price:$2,500.00 Average Price Allowed
By Medicare:
$156.41
HCPCS Code:75774 Description:Artery x-ray each vessel Average Price:$1,750.00 Average Price Allowed
By Medicare:
$128.22
HCPCS Code:92978 Description:Intravasc us heart add-on Average Price:$1,450.94 Average Price Allowed
By Medicare:
$94.89
HCPCS Code:75680 Description:Artery x-rays neck Average Price:$1,575.00 Average Price Allowed
By Medicare:
$247.19
HCPCS Code:93925 Description:Lower extremity study Average Price:$1,425.00 Average Price Allowed
By Medicare:
$174.82
HCPCS Code:36216 Description:Place catheter in artery Average Price:$1,825.00 Average Price Allowed
By Medicare:
$634.15
HCPCS Code:93880 Description:Extracranial study Average Price:$1,200.00 Average Price Allowed
By Medicare:
$176.12
HCPCS Code:78452 Description:Ht muscle image spect mult Average Price:$1,239.27 Average Price Allowed
By Medicare:
$246.07
HCPCS Code:93976 Description:Vascular study Average Price:$1,100.00 Average Price Allowed
By Medicare:
$205.55
HCPCS Code:93923 Description:Upr/lxtr art stdy 3+ lvls Average Price:$900.00 Average Price Allowed
By Medicare:
$156.25
HCPCS Code:J2785 Description:Regadenoson injection Average Price:$700.00 Average Price Allowed
By Medicare:
$52.99
HCPCS Code:93970 Description:Extremity study Average Price:$800.00 Average Price Allowed
By Medicare:
$180.26
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$680.10 Average Price Allowed
By Medicare:
$105.15
HCPCS Code:93224 Description:Ecg monit/reprt up to 48 hrs Average Price:$650.00 Average Price Allowed
By Medicare:
$95.41
HCPCS Code:76770 Description:Us exam abdo back wall comp Average Price:$660.00 Average Price Allowed
By Medicare:
$128.72
HCPCS Code:93283 Description:Icd device progr eval dual Average Price:$500.00 Average Price Allowed
By Medicare:
$61.74
HCPCS Code:93016 Description:Cardiovascular stress test Average Price:$438.37 Average Price Allowed
By Medicare:
$21.91
HCPCS Code:G0166 Description:Extrnl counterpulse, per tx Average Price:$550.00 Average Price Allowed
By Medicare:
$145.54
HCPCS Code:93567 Description:Inject suprvlv aortography Average Price:$500.00 Average Price Allowed
By Medicare:
$141.24
HCPCS Code:75898 Description:Follow-up angiography Average Price:$420.00 Average Price Allowed
By Medicare:
$84.08
HCPCS Code:93017 Description:Cardiovascular stress test Average Price:$350.00 Average Price Allowed
By Medicare:
$49.58
HCPCS Code:99217 Description:Observation care discharge Average Price:$350.00 Average Price Allowed
By Medicare:
$69.43
HCPCS Code:93306 Description:Tte w/doppler complete Average Price:$250.00 Average Price Allowed
By Medicare:
$63.85
HCPCS Code:99238 Description:Hospital discharge day Average Price:$245.00 Average Price Allowed
By Medicare:
$69.07
HCPCS Code:93018 Description:Cardiovascular stress test Average Price:$171.07 Average Price Allowed
By Medicare:
$14.84
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$245.00 Average Price Allowed
By Medicare:
$99.32
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$195.00 Average Price Allowed
By Medicare:
$69.22
HCPCS Code:93294 Description:Pm device interrogate remote Average Price:$150.00 Average Price Allowed
By Medicare:
$32.76
HCPCS Code:93016 Description:Cardiovascular stress test Average Price:$125.00 Average Price Allowed
By Medicare:
$21.59
HCPCS Code:93280 Description:Pm device progr eval dual Average Price:$140.00 Average Price Allowed
By Medicare:
$43.28
HCPCS Code:93000 Description:Electrocardiogram complete Average Price:$112.00 Average Price Allowed
By Medicare:
$18.65
HCPCS Code:93018 Description:Cardiovascular stress test Average Price:$100.00 Average Price Allowed
By Medicare:
$14.62
HCPCS Code:93295 Description:Icd device interrogat remote Average Price:$150.00 Average Price Allowed
By Medicare:
$64.85
HCPCS Code:99223 Description:Initial hospital care Average Price:$275.00 Average Price Allowed
By Medicare:
$192.42
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$223.68 Average Price Allowed
By Medicare:
$158.48
HCPCS Code:93010 Description:Electrocardiogram report Average Price:$62.00 Average Price Allowed
By Medicare:
$8.45
HCPCS Code:93005 Description:Electrocardiogram tracing Average Price:$52.00 Average Price Allowed
By Medicare:
$10.21
HCPCS Code:Q2037 Description:Fluvirin vacc, 3 yrs & >, im Average Price:$50.00 Average Price Allowed
By Medicare:
$13.99
HCPCS Code:99212 Description:Office/outpatient visit est Average Price:$70.00 Average Price Allowed
By Medicare:
$41.74
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$95.12 Average Price Allowed
By Medicare:
$69.35
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$125.00 Average Price Allowed
By Medicare:
$102.58
HCPCS Code:A9500 Description:Tc99m sestamibi Average Price:$350.00 Average Price Allowed
By Medicare:
$336.30
HCPCS Code:Q9967 Description:LOCM 300-399mg/ml iodine,1ml Average Price:$1.25 Average Price Allowed
By Medicare:
$0.14
HCPCS Code:36218 Description:Place catheter in artery Average Price:$189.00 Average Price Allowed
By Medicare:
$189.00

HCPCS Code Definitions

93016
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report
93005
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
75898
Angiography through existing catheter for follow-up study for transcatheter therapy, embolization or infusion, other than for thrombolysis
93000
Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
93010
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only
93016
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report
75774
Angiography, selective, each additional vessel studied after basic examination, radiological supervision and interpretation (List separately in addition to code for primary procedure)
75716
Angiography, extremity, bilateral, radiological supervision and interpretation
75710
Angiography, extremity, unilateral, radiological supervision and interpretation
75625
Aortography, abdominal, by serialography, radiological supervision and interpretation
37229
Revascularization, endovascular, open or percutaneous, tibial, peroneal artery, unilateral, initial vessel; with atherectomy, includes angioplasty within the same vessel, when performed
93283
Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead implantable cardioverter-defibrillator system
99217
Observation care discharge day management (This code is to be utilized to report all services provided to a patient on discharge from "observation status" if the discharge is on other than the initial date of "observation status." To report services to a patient designated as "observation status" or "inpatient status" and discharged on the same date, use the codes for Observation or Inpatient Care Services [including Admission and Discharge Services, 99234-99236 as appropriate.])
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
93224
External electrocardiographic recording up to 48 hours by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional
93280
Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system
93018
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only
A9500
Technetium tc-99m sestamibi, diagnostic, per study dose
93017
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report
93018
Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only
36218
Selective catheter placement, arterial system; additional second order, third order, and beyond, thoracic or brachiocephalic branch, within a vascular family (List in addition to code for initial second or third order vessel as appropriate)
36247
Selective catheter placement, arterial system; initial third order or more selective abdominal, pelvic, or lower extremity artery branch, within a vascular family
36252
Selective catheter placement (first-order), main renal artery and any accessory renal artery(s) for renal angiography, including arterial puncture and catheter placement(s), fluoroscopy, contrast injection(s), image postprocessing, permanent recording of images, and radiological supervision and interpretation, including pressure gradient measurements when performed, and flush aortogram when performed; bilateral
36246
Selective catheter placement, arterial system; initial second order abdominal, pelvic, or lower extremity artery branch, within a vascular family
36245
Selective catheter placement, arterial system; each first order abdominal, pelvic, or lower extremity artery branch, within a vascular family
93567
Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (List separately in addition to code for primary procedure)
93460
Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
93458
Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
93458
Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed
93459
Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography
93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
93306
Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography
93295
Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
92978
Intravascular ultrasound (coronary vessel or graft) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (List separately in addition to code for primary procedure)
78452
Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection
37225
Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with atherectomy, includes angioplasty within the same vessel, when performed
93294
Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional
36216
Selective catheter placement, arterial system; initial second order thoracic or brachiocephalic branch, within a vascular family
36215
Selective catheter placement, arterial system; each first order thoracic or brachiocephalic branch, within a vascular family
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
93976
Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study
99212
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self limited or minor. Typically, 10 minutes are spent face-to-face with the patient and/or family.
93880
Duplex scan of extracranial arteries; complete bilateral study
93923
Complete bilateral noninvasive physiologic studies of upper or lower extremity arteries, 3 or more levels (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental blood pressure measurements with bidirectional Doppler waveform recording and analysis, at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental volume plethysmography at 3 or more levels, or ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus segmental transcutaneous oxygen tension measurements at 3 or more levels), or single level study with provocative functional maneuvers (eg, measurements with postural provocative tests, or measurements with reactive hyperemia)
93925
Duplex scan of lower extremity arteries or arterial bypass grafts; complete bilateral study
93970
Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
76770
Ultrasound, retroperitoneal (eg, renal, aorta, nodes), real time with image documentation; complete
99238
Hospital discharge day management; 30 minutes or less
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
G0166
External counterpulsation, per treatment session
J2785
Injection, regadenoson, 0.1 mg
Q9967
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
Q2037
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin)

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1437152303
General Practice
7,139
1043281694
Family Practice
6,165
1639215478
Family Practice
4,485
1477538874
Diagnostic Radiology
3,969
1376546804
Pulmonary Disease
3,489
1144247693
Emergency Medicine
3,347
1053392324
Diagnostic Radiology
3,284
1750322319
Diagnostic Radiology
3,026
1477544724
Diagnostic Radiology
3,010
1912945957
Family Practice
2,709
*These referrals represent the top 10 that Dr. Tariq has made to other doctors

Publications

Hepatitis C virus infection in vitro triggers endoplasmic reticulum stress and downregulates insulin receptor substrates 1 and 2 through upregulation of cytokine signaling suppressor 3. - Acta virologica
Hepatitis C virus (HCV) infection is highly prevalent worldwide and most of HCV infections enter into chronic phase subsequently leading to insulin resistance (IR) and clinical complications. Although the clinics of chronic HCV infection is well described, there is need to better understand the molecular mechanisms of HCV-induced IR. Therefore this study was aimed to unveil the role of host genes involved in the development of HCV-induced IR. For this purpose the expression of selected genes in HCV-infected and non-infected Huh-7 cells at various time post infection (p.i.) was assayed by real-time PCR. HCV infection was found to trigger endoplasmic reticulum (ER) stress response as demonstrated by an increase in the expression of calreticulin (Cal) gene but no change in the expression of Gadd153 gene. The infection also enhanced the expression of suppressor of cytokine signaling 3 (SOCS-3), responsible for the degradation of insulin receptor substrates (IRS). Moreover, it led to a decreased expression of key signaling molecules IRS-1 and IRS-2, unchanged expression of SOCS-7 and increased expression of downstream signaling molecule Akt. Altogether these findings indicate that the HCV infection induces ER stress and IR in Huh-7 cells in vitro.
Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan. - Viral immunology
The most useful treatment for HCV infection worldwide is peg-interferon plus ribavirin, although the response varies from person to person. Hence, host genetics are significantly involved in the treatment response to HCV infection. The 2'-5' oligoadenylate synthetase (OAS) is one of the most important components of the immune system having significant antiviral functions. The aim of this study was to investigate the role of single nucleotide polymorphism (SNP) at the exon 7 splice acceptor site (SAS) of OAS1 to interferon-based therapy of HCV infection. OAS1 genotyping was performed in 140 HCV patients by restriction fragment length polymorphism polymerase chain reaction method (RFLP-PCR). These patients were enrolled for the study in 2010-2013. OAS1 SNP was also established in 120 healthy controls. Correlation of HCV genotypes, OAS1 SNP, and other factors with response to interferon therapy were statistically analyzed by SPSS 13 software. There were no significant differences in the distribution of OAS1 genotypes between healthy and patients subjects. The distribution of AG and AA genotypes of OAS1 genotypes between sustained virological responders (SVRs) and the non-responders (NRs) group were also comparable. However, Pearson chi square analysis indicated that the patients possessing a GG genotype of the OAS1 gene at exon 7 SAS demonstrated significantly positive association with treatment response to HCV infection (p=0.039). This study determined that SNP at exon 7 SAS of OAS1 was significantly associated with response to interferon-based therapy of HCV infection in our population.
Development of murine models to study Hepatitis C virus induced liver pathogenesis. - Indian journal of virology : an official organ of Indian Virological Society
Hepatitis C virus (HCV) is involved in different liver pathologies worldwide. In contemporary scenario, HCV treatment is lagging behind owing to absence of vaccines against virus. The only consideration for HCV treatment is pegylated interferon-alpha and ribavirin that results in sustained virological response in 50 % of patients. Two feasible hosts for HCV infection are chimpanzee and humans. For decades, chimpanzees are sole host to study HCV pathogenesis, but their use is limited due to ethical issues. The dilemma behind HCV therapy is the need of sustainable animal models that can help simulate in vivo conditions. We have assembled recent advances in animal models to study liver diseases for targeted therapy.
Transcript analysis of P2X receptors in PBMCs of chronic HCV patients: an insight into antiviral treatment response and HCV-induced pathogenesis. - Viral immunology
After invasion of hepatocytes and immune cells, hepatitis C virus has the ability to escape from the host immune system, leading to the progression of disease into chronic infection with associated liver morbidities. Adenosine 5'triphosphate (ATP) is released in most of the pathological events from the affected cells and acts as a signaling molecule by binding to P2X receptors expressed on the host's immune cells and activates the immune system for pro-inflammatory response. Therefore, the present study was designed to analyze the transcript expression of the ionotropic purinergic P2X receptors on peripheral blood mononuclear cells (PBMCs) of chronic HCV patients to have study the immune responses mediated by P2X receptors in chronic HCV infections.PBMCs were isolated from the collected blood samples. Transcript analysis of P2X receptors in PBMCs was done. The identity of amplified product was confirmed by sequencing PCR, while the quantification of the transcript expression was done by real time PCR. The relative expression of the P2X receptors was analyzed by unpaired Student's t test using GraphPad Prims 5 software.We found that out of seven isoforms of P2X receptors, P2X1, P2X4, P2X5, and P2X7 receptors are expressed on the PBMCs. P2X1 and P2X7 are significantly upregulated in treatment-naïve chronic HCV patients by 2.2- and 2.5-fold, respectively. However, only P2X7 expression is found increased by 2.7-fold in patients achieving sustained virological response (SVR) after antiviral treatment compared to healthy controls. The expression of P2X receptors remained unaltered in chronic HCV patients not responding to the treatment.The present study confirms the significant involvement of P2X receptors in the immune responses mediated by the PBMCs in the chronic HCV infection, which should be further investigated to devise strategies to augment the immune system against this chronic viral disease.
Role of viral and host factors in interferon based therapy of hepatitis C virus infection. - Virology journal
The current standard of care (SOC) for hepatitis C virus (HCV) infection is the combination of pegylated interferon (PEG-IFN), Ribavirin and protease inhibitor for HCV genotype 1. Nevertheless, this treatment is successful only in 70-80% of the patients. In addition, the treatment is not economical and is of immense physical burden for the subject. It has been established now, that virus-host interactions play a significant role in determining treatment outcomes. Therefore identifying biological markers that may predict the treatment response and hence treatment outcome would be useful. Both IFN and Ribavirin mainly act by modulating the immune system of the patient. Therefore, the treatment response is influenced by genetic variations of the human as well as the HCV genome. The goal of this review article is to summarize the impact of recent scientific advances in this area regarding the understanding of human and HCV genetic variations and their effect on treatment outcomes. Google scholar and PubMed have been used for literature research. Among the host factors, the most prominent associations are polymorphisms within the region of the interleukin 28B (IL28B) gene, but variations in other cytokine genes have also been linked with the treatment outcome. Among the viral factors, HCV genotypes are noteworthy. Moreover, for sustained virological responses (SVR), variations in core, p7, non-structural 2 (NS2), NS3 and NS5A genes are also important. However, all considered single nucleotide polymorphisms (SNPs) of IL28B and viral genotypes are the most important predictors for interferon based therapy of HCV infection.
Current and future therapies for hepatitis C virus infection: from viral proteins to host targets. - Archives of virology
Hepatitis C virus (HCV) infection is the most important problem across the world. It causes acute and chronic liver infection. Different approaches are in use to inhibit HCV infection, including small organic compounds, siRNA, shRNA and peptide inhibitors. This review article summarizes the current and future therapies for HCV infection. PubMed and Google Scholar were searched for articles published in English to give an insight into the current inhibitors against this life-threatening virus. HCV NS3/4A protease inhibitors and nucleoside/nucleotide inhibitors of NS5B polymerase are presently in the most progressive stage of clinical development, but they are linked with the development of resistance and viral breakthrough. Boceprevir and telaprevir are the two most important protease inhibitors that have been approved recently for the treatment of HCV infection. These two drugs are now the part of standard-of-care treatment (SOC). There are also many other drugs in phase III of clinical development. When exploring the various host-cell-targeting compounds, the most hopeful results have been demonstrated by cyclophilin inhibitors. The current SOC treatment of HCV infection is Peg-interferon, ribavirin and protease inhibitors (boceprevir or telaprevir). The future treatment of this life-threatening disease must involve combinations of therapies hitting multiple targets of HCV and host factors. It is strongly expected that the near future, treatment of HCV infection will be a combination of direct-acting agents (DAA) without the involvement of interferon to eliminate its side effects.
Phylogenetic analysis of Torque Teno Virus genome from Pakistani isolate and incidence of co-infection among HBV/HCV infected patients. - Virology journal
Torque Teno Virus (TTV) was the first single stranded circular DNA virus to be discovered that infects humans. Although there have been numerous reports regarding the prevalence of TTV from other countries of South Asia, there is severe lack of information regarding its prevalence in Pakistan. Thus the present study compiles the first indigenous report to comprehensively illustrate the incidence of the virus in uninfected and hepatitis infected population from Pakistan. Another aim of the study was to present the sequence of full length TTV genome from a local isolate and compare it with the already reported genome sequences from other parts of the world.TTV DNA was screened in the serum of 116, 100 and 40 HBV infected, HCV infected and uninfected individuals respectively. Nearly full length genome of TTV was cloned from a HBV patient. The genome sequence was subjected to in-silico analysis using CLC Workbench, ClustalW, ClustalX and TreeView. Statistical analysis was carried out in SPSS v17.0.Our results report that 89.7%, 90.0% and 92.5% of HBV, HCV patients and healthy control population were positive for TTV infection. TTV genome of 3603 bp was also cloned from a local isolate and given the identity of TPK01. The TTV genome sequence mentioned in this paper is submitted in the GenBank/EMBL/DDBJ under the accession number JN980171. Phylogenetic analysis of TPK01 revealed that the Pakistani isolate has sequence similarities with genotype 23 and 22 (Genogroup 2).The results of the current study indicate that the high frequency of TTV viremia in Pakistan conforms to the reports from other areas of the world, wherever screening of TTV DNA was performed against 5'-UTR of the genome. The high sequence diversity among TTV genome sequences and the high frequency of prevalence makes it harder to study this virus in cellular systems.
Mandibular reconstruction using osteocutaneous radial forearm flap. - Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
To describe the use of radial forearm osteocutaneous free flap in complex mandibular reconstruction.A case series.Combined Military Hospital, Rawalpindi, from January 1998 to January 2008.Patients having a small bony component and a large soft tissue mandibular defect requiring reconstruction were selected. These defects include composite through-and-through defects of the cheek in the retromolar trigone, small lateral bony defects with large intra and extra oral soft tissue defects and small central bony defects with large extra oral tissue loss. Radial forearm osteocutaneous free flap was employed. Complications and graft acceptance were determined at follow-up.Patients were followed-up for an average period of 28 months. Complications occurred in 8 patients. Wound infection and partial wound dehiscence were the most common complication observed in 3 patients. Non-union at recipient site was seen in 2 patients. Flap donor site healed uneventfully in all patients with no fractures at the donor site.The radial forearm osteocutaneous flap covers oromandibular defects with large intra-oral and extra oral soft tissue losses. Lateral and anterior mandibular defects were reconstructed satisfactorily in our series.
An overview: in vitro models of HCV replication in different cell cultures. - Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
Although much of productive research has been conducted in the field of molecular virology of Hepatitis C virus (HCV) regarding its genes, gene functions and proteins, development of an efficient cell culture model for its replication remained a focused area. Focus has been directed to establish HCV in vitro replication system. This replication system should mimic its intrahepatic pathogenesis so that antivirals should be screened and in vitro gene profiling of HCV induced pathogenesis should be worked out. Since 1990 various experimental approaches and strategies have been utilized in phase of development of a robust replication model for HCV, and success has been reported for a few genotypes. Still the work is going on to have more success in availing such robust replication models for all the genotypes. This will help to have a common antiviral strategy against HCV induced pathogenesis involving any genotype or subtype.Copyright © 2011 Elsevier B.V. All rights reserved.
Hepatitis C virus infection: molecular pathways to insulin resistance. - Virology journal
Chronic Hepatitis C virus has the potential of inducing insulin resistance and type 2 Diabetes Mellitus in vitro as well as in vivo . Structural and non-structural proteins of HCV modulate cellular gene expression in such a way that insulin signaling is hampered, concomitantly leads toward diabetes mellitus. A number of mechanisms have been proposed in regard to the HCV induced insulin resistance involving the upregulation of Inflammatory cytokine TNF-α, hypophosphorylation of IRS-1 and IRS-2, phosphorylation of Akt, up-regulation of gluconeogenic genes, accumulation of lipids and targeting lipid storage organelles. This review provides an insight of molecular mechanisms by which HCV structural and non-structural proteins can induce insulin resistance.

Map & Directions

1071 Airport Road Festus, MO 63028
View Directions In Google Maps

Nearby Doctors

1405 N Truman Blvd
Festus, MO 63028
636 332-2243
1390 Us Highway 61 Suite 2100
Festus, MO 63028
636 338-8130
1390 Us Highway 61 Ste 2100
Festus, MO 63028
636 336-6300
1500 Calvary Church Rd
Festus, MO 63028
636 332-2900
1390 Us Highway 61 Ste G1500
Festus, MO 63028
636 331-1163
1500 Calvary Church Rd
Festus, MO 63028
636 332-2900
35 Goodwin Dr
Festus, MO 63028
636 334-4141
3 Canepa Estates Rd
Festus, MO 63028
636 375-5355
620 Collins Dr
Festus, MO 63028
636 379-9152